Brief: Ocuphire Pharma Says Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
02/11/2023 12:45
Nov 2 (Reuters) - Ocuphire Pharma Inc OCUP.O :
* OCUPHIRE PHARMA ANNOUNCES SUCCESSFUL END-OF-PHASE 2
MEETING WITH
FDA FOR ORAL APX3330 IN DIABETIC RETINOPATHY
* OCUPHIRE PHARMA INC SAYS AGREEMENT ON PHASE 3 PRIMARY
ENDPOINT
OF 3-STEP WORSENING ON BINOCULAR DIABETIC RETINOPATHY SEVERITY
SCALE (DRSS) SCORE
Source text for Eikon: ID:nGNX96XZDh
Further company coverage: OCUP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data